Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

Angiotech Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Bacterial Infections

Treatments: Device: Central Venous Catheter

Study type: Interventional

Funder types: Industry

Identifiers

NCT00288418

011-ACVC05

Details and patient eligibility

About

The main purpose of this study is to determine if the Angiotech central venous catheter (CVC) is equal in effectiveness to a CVC coated with chlorhexidine and silver sulfadiazine in preventing bacterial catheter colonization. Other objectives of this study are to determine if the Angiotech CVC is equal in effectiveness to a CVC coated with chlorhexidine and silver sulfadiazine in preventing catheter-related local infection, and catheter-related bloodstream infection. This study will also assess the safety of the Angiotech CVC.

Full description

Central venous catheters are widely used for hemodynamic monitoring and the administration of fluids, drugs, and nutrition. The most frequent life-threatening complication of central venous catheter use is septicemia. Normal cutaneous flora may invade the intracutaneous tract during or after catheter insertion. The colonizing bacteria subsequently disseminate along the catheter surface and ultimately seed into the blood stream.

In the United States, a total of 250,000 cases of central venous catheter-related infections are estimated annually. Costs per infection are estimated as high as US$56,000. It is clinically imperative that effective measures be found to decrease catheter infection rates while minimizing the risk of the development of microbial resistance.

Primary Objective: The primary objective of this study is to determine the non-inferiority of the Angiotech Central Venous Catheter (CVC) when compared to the ARROWgard Blue® CVC to prevent bacterial catheter colonization.

Secondary Objectives: The secondary objectives of this study are to determine the non-inferiority of the Angiotech CVC when compared to the ARROWgard Blue® CVC to prevent:

1. catheter-related local infection; and
2. catheter-related bloodstream infection.

Safety Objectives: This study will assess the safety of the Angiotech CVC.

Enrollment: 960 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• at least 18 years of age
• Be initially hospitalized in an intensive care setting
• Require insertion of a triple-lumen central venous catheter for an anticipated period of up to 28 days
• If female and of child-bearing potential, provide evidence of a negative pregnancy test

Exclusion criteria

• Has a life expectancy of less than one month
• Is pregnant
• Has a history of anaphylactic reactions, including reactions to contrast dyes
• Has a history of allergy to 5-fluorouracil (5-FU) or chlorhexidine

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

960 participants in 2 patient groups

ARROWgard Blue® CVC

Active Comparator group

Description:

7-French x 20-cm, triple lumen, short-term CVC

Treatment:

Device: Central Venous Catheter

Angiotech CVC

Experimental group

Description:

A 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU

Treatment:

Device: Central Venous Catheter